Peptide Industry intermediate
Peptide Clinical Trials
Current landscape of peptide therapeutics in clinical development and trials.
By Encyclopeptide Editorial | 1 min read
clinical-trials development pipeline industry
Overview
Hundreds of peptide candidates are in clinical trials across metabolic, oncology, neurological, and rare disease indications.
Trial Phases
- Phase I: Safety and dosing in healthy volunteers
- Phase II: Efficacy signals in target population
- Phase III: Confirmatory pivotal studies
- Phase IV: Post-marketing surveillance
Therapeutic Areas
- Metabolic diseases: GLP-1 agonists, amylin analogs
- Oncology: Peptide vaccines, drug conjugates
- Rare diseases: Enzyme replacement therapies
- Neurology: Neuropeptide-based approaches
Success Rates
Peptide drugs generally show higher success rates than small molecules due to their specificity and safety profiles.
References
- Source: ENCP Peptide Database
- Category: Peptide Industry
Test Your Knowledge
Reinforce what you learned about Peptide Clinical Trials with interactive quizzes on Wikipept.
Take a Quiz on Wikipept